SUM_M(2)×\timesUC_C(1) Gauge Symmetry in High TcT_c Superconductivity

The square lattice structure of $CuO_2$ layers and the strongly correlated property of electrons indicate that the high $T_c$ superconductivity in cuprates can be described by a SO$_M$(5) coherent pairing state in which a SU$_M$(2)$\times$U$_C$(1) gauge symmetry is embedded. The spin and charge fluctuations that characterize the low energy magnetic excitations in cuprates are controlled by this intrinsic SU$_M$(2)$\times$U$_C$(1) gauge symmetry.Comment: 4 pages Revtex fil

Wind-Blown Bubbles around Evolved Stars

Most stars will experience episodes of substantial mass loss at some point in their lives. For very massive stars, mass loss dominates their evolution, although the mass loss rates are not known exactly, particularly once the star has left the main sequence. Direct observations of the stellar winds of massive stars can give information on the current mass-loss rates, while studies of the ring nebulae and HI shells that surround many Wolf-Rayet (WR) and luminous blue variable (LBV) stars provide information on the previous mass-loss history. The evolution of the most massive stars, (M > 25 solar masses), essentially follows the sequence O star to LBV or red supergiant (RSG) to WR star to supernova. For stars of mass less than 25 solar masses there is no final WR stage. During the main sequence and WR stages, the mass loss takes the form of highly supersonic stellar winds, which blow bubbles in the interstellar and circumstellar medium. In this way, the mechanical luminosity of the stellar wind is converted into kinetic energy of the swept-up ambient material, which is important for the dynamics of the interstellar medium. In this review article, analytic and numerical models are used to describe the hydrodynamics and energetics of wind-blown bubbles. A brief review of observations of bubbles is given, and the degree to which theory is supported by observations is discussed.Comment: To be published as a chapter in 'Diffuse Matter from Star Forming Regions to Active Galaxies' - A volume Honouring John Dyson. Eds. T. W. Harquist, J. M. Pittard and S. A. E. G. Falle. 22 pages, 12 figure

Factors Associated with Revision Surgery after Internal Fixation of Hip Fractures

Background: Femoral neck fractures are associated with high rates of revision surgery after management with internal fixation. Using data from the Fixation using Alternative Implants for the Treatment of Hip fractures (FAITH) trial evaluating methods of internal fixation in patients with femoral neck fractures, we investigated associations between baseline and surgical factors and the need for revision surgery to promote healing, relieve pain, treat infection or improve function over 24 months postsurgery. Additionally, we investigated factors associated with (1) hardware removal and (2) implant exchange from cancellous screws (CS) or sliding hip screw (SHS) to total hip arthroplasty, hemiarthroplasty, or another internal fixation device. Methods: We identified 15 potential factors a priori that may be associated with revision surgery, 7 with hardware removal, and 14 with implant exchange. We used multivariable Cox proportional hazards analyses in our investigation. Results: Factors associated with increased risk of revision surgery included: female sex, [hazard ratio (HR) 1.79, 95% confidence interval (CI) 1.25-2.50; P = 0.001], higher body mass index (fo

Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial

Background Previous evidence indicates that adjuvant, short-course androgen deprivation therapy (ADT) improves metastasis-free survival when given with primary radiotherapy for intermediate-risk and high-risk localised prostate cancer. However, the value of ADT with postoperative radiotherapy after radical prostatectomy is unclear. Methods RADICALS-HD was an international randomised controlled trial to test the efficacy of ADT used in combination with postoperative radiotherapy for prostate cancer. Key eligibility criteria were indication for radiotherapy after radical prostatectomy for prostate cancer, prostate-specific antigen less than 5 ng/mL, absence of metastatic disease, and written consent. Participants were randomly assigned (1:1) to radiotherapy alone (no ADT) or radiotherapy with 6 months of ADT (short-course ADT), using monthly subcutaneous gonadotropin-releasing hormone analogue injections, daily oral bicalutamide monotherapy 150 mg, or monthly subcutaneous degarelix. Randomisation was done centrally through minimisation with a random element, stratified by Gleason score, positive margins, radiotherapy timing, planned radiotherapy schedule, and planned type of ADT, in a computerised system. The allocated treatment was not masked. The primary outcome measure was metastasis-free survival, defined as distant metastasis arising from prostate cancer or death from any cause. Standard survival analysis methods were used, accounting for randomisation stratification factors. The trial had 80% power with two-sided α of 5% to detect an absolute increase in 10-year metastasis-free survival from 80% to 86% (hazard ratio [HR] 0·67). Analyses followed the intention-to-treat principle. The trial is registered with the ISRCTN registry, ISRCTN40814031, and ClinicalTrials.gov, NCT00541047. Findings Between Nov 22, 2007, and June 29, 2015, 1480 patients (median age 66 years [IQR 61–69]) were randomly assigned to receive no ADT (n=737) or short-course ADT (n=743) in addition to postoperative radiotherapy at 121 centres in Canada, Denmark, Ireland, and the UK. With a median follow-up of 9·0 years (IQR 7·1–10·1), metastasis-free survival events were reported for 268 participants (142 in the no ADT group and 126 in the short-course ADT group; HR 0·886 [95% CI 0·688–1·140], p=0·35). 10-year metastasis-free survival was 79·2% (95% CI 75·4–82·5) in the no ADT group and 80·4% (76·6–83·6) in the short-course ADT group. Toxicity of grade 3 or higher was reported for 121 (17%) of 737 participants in the no ADT group and 100 (14%) of 743 in the short-course ADT group (p=0·15), with no treatment-related deaths. Interpretation Metastatic disease is uncommon following postoperative bed radiotherapy after radical prostatectomy. Adding 6 months of ADT to this radiotherapy did not improve metastasis-free survival compared with no ADT. These findings do not support the use of short-course ADT with postoperative radiotherapy in this patient population

Age at Diagnosis of Pheochromocytoma Differs According to Catecholamine Phenotype and Tumor Location

Ages at diagnosis of pheochromocytomas and paragangliomas vary according to the catecholamine phenotypes and locations of tumors